Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC chemokine ligand 3/macrophage inflammatory protein-1á

Cancer Research

Volumn 70, Issue 16, 2010, Pages 6556-6565

  Iida, Noriho ^a   Nakamoto, Yasunari ^a   Baba, Tomohisa ^a   Nakagawa, Hidetoshi ^a   Mizukoshi, Eishiro ^a   Naito, Makoto ^b   Mukaida, Naofumi ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR1; ECI 301; GAMMA INTERFERON; GLYCOPROTEIN P 15095; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; UNCLASSIFIED DRUG; CCR1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATOMA CELL; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CATHETER ABLATION; DEFICIENCY; IMMUNOLOGY; LIVER NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; CATHETER ABLATION; CELL LINE, TUMOR; CHEMOKINE CCL3; FEMALE; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTORS, CCR1; T-LYMPHOCYTES;

EID: 77955741107     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0096     Document Type: Article

References (42)

1. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
2. + T cell-dendritic cell interaction. Nature 2006;440:890-5.
3. Sozzani S. Dendritic cell trafficking: more than just chemokines. Cytokine Growth Factor Rev 2005;16:581-92. (Pubitemid 41505518)
4. Iida N, Nakamoto Y, Baba T, et al. Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1-and 5-dependent manner in mice. J Leukoc Biol 2008;84:1001-10.
5. Tsuchiyama T, Nakamoto Y, Sakai Y, et al. Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. J Immunol 2007;178:574-83. (Pubitemid 46033641)
6. Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res 2003;63:5505-12. (Pubitemid 37139870)
7. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 2004;113:774-83. (Pubitemid 38544171)
8. Zerbini A, Pilli M, Penna A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 2006;66:1139-46. (Pubitemid 43165983)
9. Ali MY, Grimm CF, Ritter M, et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol 2005;43:817-22. (Pubitemid 41414507)
10. Brok MH, Sutmuller RP, Voort R, et al. In situ tumor ablation creates antigen source for the generation of antitumor immunity. Cancer Res 2004;64:4024-9.
11. Wissniowski TT, Hünsler J, Neureiter D, et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 2003;63:6496-500. (Pubitemid 37255202)
12. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-7. (Pubitemid 30640096)
13. Hunter MG, Bawden L, Brotherton D, et al. BB-10010: an active variant of human macrophage inflammatory protein-1α with improved pharmaceutical properties. Blood 1995;86:4400-8.
14. Clemons MJ, Marshall E, Dürig J, et al. A randomized phase-II study of BB-10010 (macrophage inflammatory protein-1α) in patients with advanced breast cancer receiving 5-fluorouracil, Adriamycin, and cyclophosphamide chemotherapy. Blood 1998;92:1532-40.
15. Zhang Y, Yoneyama H, Wang Y, et al. Mobilization of dendritic cell precursors into the circulation by administration of MIP-1α in mice. J Natl Cancer Inst 2004;96:201-9. (Pubitemid 38263179)
16. + T cells in response to MIP-1α and MIP-1β. Science 1993;260:355-8.
17. Shiraishi K, Ishiwata Y, Nakagawa K, et al. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1α. Clin Cancer Res 2008;14:1159-66. (Pubitemid 351302564)
18. Isoai A, Kimura H, Reichert A, et al. Production of D-amino acid oxidase of Trigonopsis variabilis in Schizosaccharomyces pombe and the characterization of biocatalysts prepared with recombinant cells. Biotechnol Bioeng 2002;80:22-32.
19. Lu P, Nakamoto Y, Nemoto-Sakai Y, et al. Potential interaction between CCR1 and its ligand, CCL3, induced by endogeneously produced interleukin-1 in human hepatomas. Am J Pathol 2003;162:1249-58. (Pubitemid 36350669)
20. Lu P, Li L, Liu G, Rooijen N, Mukaida N, Zhang X. Opposite roles of CCR2 and CX3CR1 macrophages in alkali-induced corneal neovascularization. Cornea 2009;28:562-9.
21. Sadahira Y, Yasuda T, Yoshino T, et al. Impaired splenic erythropoiesis in phlebotomized mice injected with CL2MDP-liposome: an experimental model for studying the role of stromal macrophages in erythropoiesis. J Leukoc Biol 2000;68:464-70.
22. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801. (Pubitemid 23174709)
23. Velázquez RF, Rodríguez M, Navascués CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-7.
24. Okita K. Management of hepatocellular carcinoma in Japan. J Gastroenterol 2006;41:100-6.
25. Tateishi R, Shiina S, Ohki T, et al. Treatment strategy for hepatocellular carcinoma: expanding the indication for radiofrequency ablation. J Gastroenterol 2009;44 Suppl:142-6.
26. Homey B, Müller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immnol 2002;2:175-84.
27. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50.
28. Dell'Agnola C, Biragyn A. Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Rev Vaccines 2007;6:267-83. (Pubitemid 46607460)
29. Tsuchiyama T, Nakamoto Y, Sakai Y, Mukaida N, Kaneko S. Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation. Cancer Sci 2008;99:2075-82.
30. Nakashima E, Ova A, Kubota YA. A candidate for cancer gene therapy: MIP-1α gene transfer to an adenocarcinoma cell line reduced tumorigenesity and induced protective immunity in immunocompetent mice. Pharm Res 1996;13:1896-901. (Pubitemid 27034126)
31. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010;327:656-61.
32. Randolph GJ, Ochando J, Partida-Sánchez S. Migration of dendritic cell subsets and their precursors. Annu Rev Immunol 2008;26:293-316. (Pubitemid 351600378)
33. López-Bravo M, Ardavín C. In vivo induction of immune responses to pathogens by conventional dendritic cells. Immunity 2008;29:343-51.
34. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumor angiogenesis. Nat Rev Cancer 2008;8:618-31.
35. Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanism of promalignant activity. Cancer Res 2002;62:1093-102. (Pubitemid 34160293)
36. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001;166:6483-90. (Pubitemid 32467185)
37. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61. (Pubitemid 46067386)
38. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691-701. (Pubitemid 41815875)
39. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9. (Pubitemid 47517504)
40. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006;203:1259-71.
41. Schueller G, Kettenbach J, Sedivy R, et al. Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo. Int J Oncol 2004;24:609-13.
42. Nikfarjam M,Muralidharan V, Su K, Malcontenti-Wilson C, Christophi C. Patterns of heat shock protein (HSP70) expression and Kupffer cell activity following thermal ablation of liver and colorectal liver metastasis. Int J Hyperthermia 2005;21:319-32. (Pubitemid 40975182)